In September 2021 we announced a global licensing and research collaboration with Eli Lilly and Company. The partnership focuses on the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s proprietary Axiomer® RNA editing platform to progress up to five new drug targets toward clinical development and commercialization.
Axiomer license with Lilly
ProQR’s Axiomer® platform technology enables the specific editing of single nucleotides in RNA. The technology is based on editing oligonucleotides designed to recruit endogenous ADAR enzymes (Adenosine Deaminases Acting on RNA) to edit a selected target adenosine. This technology could be applied to potentially reverse the more than 20,000 G to A mutations in the human population that are known to cause disease.